Figure legends
Figure 1. Flow diagram depicting the study selection process.
Figure 2. MHD at three time points: baseline and after the
administration of 3 and 6 doses of the correspondent treatment. Patients
were clustered as follows: (A) CM treated with erenumab, (B) CM treated
with galcanezumab, (C) EM treated with erenumab and (D) EM treated with
galcanezumab. Dots/squares represent the means and vertical lines ± the
standard error of the mean. * Represents values from treated groups that
differ significantly from baseline status (RM One Way ANOVA, p
< 0.05).
Figure 3. AMSMD at three time points: baseline and after the
administration of 3 and 6 doses of the correspondent treatment. Patients
were clustered as follows: (A) CM treated with erenumab, (B) CM treated
with galcanezumab, (C) EM treated with erenumab and (D) EM treated with
galcanezumab. Dots/squares represent the means and vertical lines ± the
standard error of the mean. * Represents values from treated groups that
differ significantly from baseline status (RM One Way ANOVA, p
< 0.05).
Figure 4. HIT-6 scores at three time points: baseline and after
the administration of 3 and 6 doses of the correspondent treatment.
Patients were clustered as follows: (A) CM treated with erenumab, (B) CM
treated with galcanezumab, (C) EM treated with erenumab and (d) EM
treated with galcanezumab. Columns represent the means and vertical
lines ± the standard error of the mean. * Represents values from treated
groups that differ significantly from baseline status (RM One Way ANOVA,
p < 0.05).
Figure 5. MIDAS scores at three time points: baseline and after
the administration of 3 and 6 doses of the correspondent treatment.
Patients were clustered as follows: (A) CM treated with erenumab, (B) CM
treated with galcanezumab, (C) EM treated with erenumab and (D) EM
treated with galcanezumab. Columns represent the means and vertical
lines ± the standard error of the mean. * Represents values from treated
groups that differ significantly from baseline status (RM One Way ANOVA,
p < 0.05).
Figure 6. VAS scores at three time points: baseline and after
the administration of 3 and 6 doses of the correspondent treatment.
Patients were clustered as follows: (A) CM treated with erenumab, (B) CM
treated with galcanezumab, (C) EM treated with erenumab and (D) EM
treated with galcanezumab. Columns represent the means and vertical
lines ± the standard error of the mean. * Represents values from treated
groups that differ significantly from baseline status (RM One Way ANOVA,
p < 0.05). # Represents values from treated groups that
differ significantly from each other.